3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Papillomavirus Infections
7
Uterine Cervical Neoplasms
5
Neuroendocrine Tumors
4
Neoplasms
4
Autoimmune Diseases
3
Ovarian Neoplasms
2
Myasthenia Gravis
2
Mesothelioma, Malignant
2
Lung Neoplasms
2
Venous Thrombosis
1
Venous Thromboembolism
1
Uterine Cervical Dysplasia
1
Thyroid Diseases
1
Thrombosis
1
Squamous Intraepithelial Lesions
1
Retinal Telangiectasis
1
Renal Insufficiency
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Hairy Cell
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
Cyclophosphamide
67
Dexamethasone
52
Peripheral Blood Stem Cell Transplantation
37
Lenalidomide
37
Rituximab
35
fludarabine phosphate
34
Bortezomib
30
Filgrastim
27
Etoposide
27
Cytarabine
25
Carboplatin
25
Busulfan
23
Radiotherapy
22
Melphalan
22
Gemcitabine
22
Cyclosporine
21
pomalidomide
20
fludarabine
20
Whole-Body Irradiation
20
Mycophenolic Acid
20
Paclitaxel
19
Methotrexate
18
venetoclax
17
Cisplatin
17
pembrolizumab
16
Calcium Dobesilate
16
Bevacizumab
16
Tacrolimus
14
Antilymphocyte Serum
14
Nivolumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Recurrence
×
Data Collection
×
Clear all
NCT02262273
2017-03-01
OSCA
AstraZeneca
Completed
2,123 enrolled